Ninety percent of people with Down syndrome, also known as trisomy 21, will develop Alzheimer’s. Yet this population has never been included in the clinical research that has underpinned regulatory approvals for the medicines to help treat it.
The vaccine is designed to stimulate the immune system to produce antibodies against a build-up of the protein Abeta (Aβ) in the brain. Reducing the build-up of this protein, may slow memory loss seen in Alzheimer’s disease.
Do you or a loved one have Down syndrome, aged between 35-50 and have a family member or friend who could be a study partner? If so, you could be working with the Learning Disability and Research teams in Oxford Health, to help find out if this vaccine is effective.
More information about the study can be found on the ABATE study website.
You can make further enquiries and register your interest in participating in the study by emailing: email@example.com
You can read about part 1 of the ABATE study on the Oxford Health NHS Foundation Trust website.
We are sorry you did not find this page helpful
Tell us how we can improve this page
Published: 11 January 2024